AstraZeneca’s experimental drug baxdrostat demonstrated statistically significant reductions in systolic blood pressure among patients with uncontrolled or resistant hypertension in a pivotal late-stage trial. The aldosterone synthase inhibitor’s efficacy and favorable safety profile bolster AstraZeneca’s $1.3 billion acquisition of CinCor Pharma earlier this year. The data, pending detailed presentation at the European Society of Cardiology Congress, highlights a novel treatment approach in a field with limited recent innovation. Baxdrostat’s potential for a multibillion-dollar market underlines the strategic value of AstraZeneca’s investment.